Seganserin

Seganserin
Clinical data
Other names	R-56413; R56413
Drug class	Serotonin 5-HT2 receptor antagonist; Serotonin 5-HT2A receptor antagonist
ATC code	None;
Pharmacokinetic data
Onset of action	TmaxTooltip Time to peak levels: 1 hour
Elimination half-life	26 hours
Identifiers
	IUPAC name 3-[2-[4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl]ethyl]-2-methylpyrido[1,2-a]pyrimidin-4-one;
CAS Number	87729-89-3;
PubChem CID	71767;
DrugBank	DB19608;
ChemSpider	64806;
UNII	197HL4EZCC;
ChEMBL	ChEMBL1742436;
CompTox Dashboard (EPA)	DTXSID50236594 ;
Chemical and physical data
Formula	C29H27F2N3O
Molar mass	471.552 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC(=C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F)CC3;
	InChI InChI=1S/C29H27F2N3O/c1-20-26(29(35)34-16-3-2-4-27(34)32-20)15-19-33-17-13-23(14-18-33)28(21-5-9-24(30)10-6-21)22-7-11-25(31)12-8-22/h2-12,16H,13-15,17-19H2,1H3; Key:ZGUPMFYFHHSNFK-UHFFFAOYSA-N;

Seganserin (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name; developmental code name R-56413) is a selective serotonin 5-HT₂ receptor antagonist which was studied for the treatment of insomnia and anxiety but was never marketed.^[2]^[3]^[1]^[4]^[5]^[6] It acts as a dual serotonin 5-HT_2A and 5-HT_2C receptor antagonist.^[3]^[4] The drug blocks the head-twitch response induced by serotonin precursor 5-hydroxytryptophan (5-HTP) and the psychedelic drug mescaline in rodents.^[7] It has been found to enhance slow wave sleep (SWS) in clinical studies.^[3]^[4]^[5]^[8]^[1] The drug's time to peak levels is 1 hour and its elimination half-life is 26 hours.^[1] Seganserin reached phase 2 clinical trials prior to the discontinuation of its development.^[2] It was first described in the scientific literature by 1985.^[9]^[10]